Loading…
Loading…
EQUITY / NASDAQ · XNCM
China SXT Pharmaceuticals, Inc.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2025 – 03/31/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.0308 USD · -2.3654%
Observed: Oct 5, 2026, 11:39 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 2.08 USD · Volume 950,480
251 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
5 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2025 – 03/31/2026 · Units
| Metric | 2026 / Year end | 2025 / Year end | Change |
|---|---|---|---|
| Operating profit | -7,122,933 USD | -2,680,479 USD | — |
| Net income | -6,205,085 USD | -3,303,652 USD | — |
| Operating cash flow | -4,017,456 USD | -2,345,333 USD | — |
| Cash and cash equivalents | 28,175,865 USD | 18,099,019 USD | +55.68% |
| Total liabilities | 5,047,152 USD | 6,223,746 USD | -18.90% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Year end04/01/2025 – 03/31/2026ConsolidatedUnits · USD | 2025 / Year end04/01/2024 – 03/31/2025ConsolidatedUnits · USD | 2024 / Year end04/01/2023 – 03/31/2024ConsolidatedUnits · USD | 2023 / Year end03/31/2023 – 03/31/2023ConsolidatedUnits · USD | 2023 / Year end04/01/2022 – 03/31/2023ConsolidatedUnits · USD |
|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 28,175,865 USD | 18,099,019 USD | — | — | — |
| Financing cash flowCash flow statement | 14,433,521 USD | 8,399,153 USD | -2,624,428 USD | — | 2,941,602 USD |
| Gross profitIncome statement | 248,702 USD | 367,427 USD | 553,971 USD | — | 426,271 USD |
| Investing cash flowCash flow statement | -1,250,921 USD | 63,516 USD | 26,423 USD | — | -12,303 USD |
| Net incomeIncome statement | -6,205,085 USD | -3,303,652 USD | -3,098,532 USD | — | -5,934,772 USD |
| Operating cash flowCash flow statement | -4,017,456 USD | -2,345,333 USD | -1,928,053 USD | — | -80,757 USD |
| Operating profitIncome statement | -7,122,933 USD | -2,680,479 USD | -2,515,217 USD | — | -5,607,509 USD |
| Total assetsBalance sheet | 34,754,574 USD | 21,663,508 USD | — | — | — |
| Total equityBalance sheet | 29,707,422 USD | 15,439,762 USD | 13,930,446 USD | 14,691,295 USD | 14,691,295 USD |
| Total liabilitiesBalance sheet | 5,047,152 USD | 6,223,746 USD | — | — | — |
| Capital expendituresCash flow statement | — | 2,023 USD | 7,063 USD | — | — |
| Report source | Open report ↗ Published: 07/01/2026 | Open report ↗ Published: 07/01/2026 | Open report ↗ Published: 07/01/2026 | Open report ↗ Published: 07/01/2026 | Open report ↗ Published: 07/31/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.